![Camilla Sylvest](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Camilla Sylvest
Direktor/Vorstandsmitglied bei
ARGENX SE
Vermögen: 3 Mio $ am 31.07.2026
Profil
Camilla Sylvest is currently an Independent Non-Executive Director at argenx SE since 2022, a Director at Zealand Pharma A starting in 2026, and an Independent Director at Getinge AB starting in 2026.
Former roles include Vice Chairman at World Diabetes Foundation, Independent Director at Danish Crown A, Senior Vice President & General Manager-Germany at Novo Nordisk Pharma GmbH, and EVP-Commercial Strategy & Corporate Affairs at Novo Nordisk A from 2017 to 2025.
Education includes a graduate degree from the University of Southern Denmark in 1998 and an MBA from Scandinavian International Management Institute in 2003.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ARGENX SE 0 % | 30.06.2026 | 3.049 ( 0 % ) | 3 Mio $ | 31.07.2026 |
Aktive Positionen von Camilla Sylvest
| Unternehmen | Position | Beginn |
|---|---|---|
| ARGENX SE | Direktor/Vorstandsmitglied | 08.09.2022 |
| GETINGE AB | Direktor/Vorstandsmitglied | 21.04.2026 |
| ZEALAND PHARMA A/S | Direktor/Vorstandsmitglied | 26.05.2026 |
Ehemalige bekannte Positionen von Camilla Sylvest
| Unternehmen | Position | Ende |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | 03.04.2025 |
World Diabetes Foundation
 World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Direktor/Vorstandsmitglied | - |
Danish Crown A/S
 Danish Crown A/S Food: Meat/Fish/DairyConsumer Non-Durables Engages in processing and sale of chilled & frozen meat products, pork, beef, poultry and lamb | Direktor/Vorstandsmitglied | - |
Novo Nordisk Pharma GmbH
 Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Corporate Officer/Principal | - |
Ausbildung von Camilla Sylvest
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
73
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Getinge AB
 Getinge AB Medical SpecialtiesHealth Technology Manufactures and distributes medical devices and disinfectants | Health Technology |
Zealand Pharma A/S
 Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
University of Southern Denmark
 University of Southern Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Scandinavian International Management Institute
 Scandinavian International Management Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Danish Crown A/S
Danish Crown A/S Food: Meat/Fish/DairyConsumer Non-Durables Engages in processing and sale of chilled & frozen meat products, pork, beef, poultry and lamb | Consumer Non-Durables |
argenx SE
 argenx SE BiotechnologyHealth Technology Develops therapies and medicines for the treatment of autoimmune diseases | Health Technology |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
